Company Overview and News

 
TK Maxx set to go head to head with Warehouse on discounted big brands

2018-10-11 nzherald.co.nz
Big box outlet retailer TK Maxx is tipped to launch in New Zealand and could open its first store - in Auckland - as early as next year.
WHOSY WHGPF WHS

 
PB Tech cops $77,000 fine over extended warranties

2018-10-01 nzherald.co.nz
PB Technologies has been fined $77,000 in the Auckland District Court after pleading guilty to 14 charges brought by the Commerce Commission over its extended warranties.
WHOSY WHGPF WHS

 
The Warehouse's profit slips 13 per cent to $59 million

2018-09-20 nzherald.co.nz
New Zealand's largest retailer made $59 million in profit in the year to July, down 13.4 per cent on the year before.
WHOSY WHGPF WHS

 
Digital price tags: The future of retailing?

2018-09-16 nzherald.co.nz
Digital price tags might be popping up in shops all over the country, but experts say they're not likely to become a norm any time soon.
WHOSY WHGPF WHS

8
The Warehouse Group looking for chief information officer after Timothy Kasbe departs

2018-09-05 nzherald.co.nz - 1
The Warehouse Group will begin the search for a new chief information officer following the departure of Timothy Kasbe.
SHLD WHOSY SHLDW WHGPF WHS

 
NZ shares fall, led lower by Sky TV

2018-08-31 nzherald.co.nz
New Zealand shares dipped, led lower by Sky Network Television and Tourism Holdings, but gained over 4 per cent in the month after a busy earnings season.
TME TRMEF AIR FCREY RYM WHGPF ANZFY AIZ FTRRF CGF WHS SKT SYKWF WHOSY TME SKKTY SML FBU RHCGF THO FRCEF FBU THL ANZLY RYHTY ANZFF TDMEY

 
Spark New Zealand Limited ADR (SPKKY) Q4 2018 Results - Earnings Call Transcript

2018-08-24 seekingalpha
Spark New Zealand Limited ADR (OTCPK:SPKKY) Q4 2018 Results Earnings Conference Call August 21, 2018 6:00 PM ET
WHOSY SPKKY NZTCY SPK NZTCF WHGPF WHS

 
Noel Leeming guilty of misleading consumers after Commerce Commission investigation

2018-08-24 nzherald.co.nz
Technology and appliance retailer Noel Leeming has admitted misleading consumers' rights after customer complaints led to an investigation by the Commerce Commission.
WHOSY WHGPF WHS

1
The Warehouse unveils 'concept' store to test market, rolls out digital price tags

2018-08-17 nzherald.co.nz - 1
New Zealand's biggest retailer, The Warehouse, is using a revamped shop as a concept store to test shopper preferences and the retail market.
WHOSY WHGPF WHS

 
Saying bye to plastic: What Kiwi shops say about Government's plan to ban single-use plastic bags

2018-08-10 nzherald.co.nz
New Zealand retailers - big and small - have welcomed the Government's plans to phase out single-use plastic bags over the next year.
WHOSY WHGPF WHS

 
Single-use plastic bags will be phased out over the next year, says Jacinda Ardern

2018-08-09 nzherald.co.nz
Single-use plastic bags will be banned in New Zealand and are to be phased out over the next 12 months, the Government says.
WHOSY WHGPF WHS

 
New World, PAK'nSAVE, Liquorland and others to ban plastic bags from 2019

2018-08-02 nzherald.co.nz
Foodstuffs has taken the war against plastic bags a step further, announcing today that all its retail and wholesale brands will no longer offer plastic checkout bags from 1 January 2019.
BGR WHOSY WHGPF WHS

2
Economy Hub: Stephen Tindall - life after The Warehouse

2018-07-19 nzherald.co.nz - 2
It's only as we're driving away from the interview at his small Tindall Foundation office in Takapuna that I realise I've forgotten to acknowledge that at any stage.
WHOSY WHGPF WHS

 
60 leading Kiwi CEOs commit to climate action

2018-07-11 nzherald.co.nz
Bosses of 60 companies that make up nearly half of New Zealand's greenhouse gas emissions have pledged to take a fresh stand on climate change.
CEN AIR ZNRGF WHGPF ZEL ANZFY COENY AIZ WHS COENF ZNZ WHOSY ANZLY CEN ANZFF

1
Warehouse restructure would affect 769 people nationally

2018-07-05 nzherald.co.nz - 1
The Warehouse Group has told First Union that its latest restructure has nothing to do with economic savings.
WHOSY WHGPF WHS

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...